Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
| ▸ | ADK | P55263 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 2/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17952983 | 0.94 | L3MBTL1 (0.35) | DRD2SMN1; SMN2HTR1ALMNATSHR | |
| SCHEMBL17169024 | 0.91 | SMN1; SMN2 (0.39) | SMN1; SMN2SRD5A1PRCPLMNATSHR | |
| SCHEMBL17952987 | 0.86 | JAK2 (0.38) | SMN1; SMN2SRD5A1 | |
| SCHEMBL17952990 | 0.86 | SMN1; SMN2 (0.34) | DRD2SMN1; SMN2HTR1AHTR7SRD5A1 | |
| SCHEMBL19336705 | 0.85 | DRD2 (0.34) | DRD2SMN1; SMN2HTR1AHTR7SRD5A1 | |
| SCHEMBL17169025 | 0.84 | MEN1 (0.38) | SMN1; SMN2SRD5A1 | |
| SCHEMBL17082306 | 0.84 | HTR1A (0.33) | DRD2SMN1; SMN2HTR1AHTR7SRD5A1 | |
| SCHEMBL17952986 | 0.82 | RXRA (0.33) | SMN1; SMN2HTR1AHTR7TSHR | |
| SCHEMBL17082245 | 0.82 | DRD2 (0.32) | DRD2SMN1; SMN2HTR1AHTR7SRD5A1 | |
| SCHEMBL17952995 | 0.81 | ROCK1 (0.35) | SMN1; SMN2SRD5A1LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790240-B2 | Ligand compound, a preparation method thereof, a transition metal compound, and a preparation method thereof | LG CHEM, LTD. (KR) | 2017-10-17 | — | — | US | disclosed |
| US-20160215004-A1 | A NOVEL LIGAND COMPOUND, A PREPARATION METHOD THEREOF, A TRANSITION METAL COMPOUND, AND A PREPARATION METHOD THEREOF | LG CHEM, LTD. (KR) | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160215004-A1 | A NOVEL LIGAND COMPOUND, A PREPARATION METHOD THEREOF, A TRANSITION METAL COMPOUND, AND A PREPARATION METHOD THEREOF | CD40LG, OSTC, TNFSF10 | DRD2 2028/4885SMN1; SMN2 4715/4885HTR1A 4211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.